🚀 VC round data is live in beta, check it out!
Ocugen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ocugen and similar public comparables like Zura Bio, Lexicon Pharmaceuticals, TTY Biopharm, uniQure and more.
Ocugen Overview
About Ocugen
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Founded
2000
HQ
Employees
95
Website
Financials (LTM)
EV
$644M
Ocugen Financials
Ocugen reported last 12-month revenue of $4M.
In the same LTM period, Ocugen generated had net loss of ($69M).
Revenue (LTM)
Ocugen P&L
In the most recent fiscal year, Ocugen reported revenue of $4M and EBITDA of ($60M).
Ocugen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | $4M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($60M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1366%) | XXX | XXX | XXX |
| EBIT Margin | (1688%) | XXX | (1426%) | XXX | XXX | XXX |
| Net Profit | ($69M) | XXX | ($68M) | XXX | XXX | XXX |
| Net Margin | (1799%) | XXX | (1537%) | XXX | XXX | XXX |
| Net Debt | — | — | $10M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ocugen Stock Performance
Ocugen has current market cap of $643M, and enterprise value of $644M.
Market Cap Evolution
Ocugen's stock price is $1.97.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $644M | $643M | 0.0% | XXX | XXX | XXX | $-0.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOcugen Valuation Multiples
Ocugen trades at 167.8x EV/Revenue multiple, and (10.7x) EV/EBITDA.
EV / Revenue (LTM)
Ocugen Financial Valuation Multiples
As of March 18, 2026, Ocugen has market cap of $643M and EV of $644M.
Equity research analysts estimate Ocugen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ocugen has a P/E ratio of (9.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $643M | XXX | $643M | XXX | XXX | XXX |
| EV (current) | $644M | XXX | $644M | XXX | XXX | XXX |
| EV/Revenue | 167.8x | XXX | 145.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (10.7x) | XXX | XXX | XXX |
| EV/EBIT | (9.9x) | XXX | (10.2x) | XXX | XXX | XXX |
| P/E | (9.3x) | XXX | (9.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (11.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ocugen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ocugen Margins & Growth Rates
Ocugen's revenue in the last 12 month grew by 150%.
Ocugen's revenue per employee in the last FY averaged $0.0M.
Ocugen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 150% | XXX | (62%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1366%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 702% | XXX | 625% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1064% | XXX | 901% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1526% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ocugen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zura Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexicon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| TTY Biopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| uniQure | XXX | XXX | XXX | XXX | XXX | XXX |
| TYK Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ocugen M&A Activity
Ocugen acquired XXX companies to date.
Last acquisition by Ocugen was on XXXXXXXX, XXXXX. Ocugen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ocugen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOcugen Investment Activity
Ocugen invested in XXX companies to date.
Ocugen made its latest investment on XXXXXXXX, XXXXX. Ocugen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ocugen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ocugen
| When was Ocugen founded? | Ocugen was founded in 2000. |
| Where is Ocugen headquartered? | Ocugen is headquartered in United States. |
| How many employees does Ocugen have? | As of today, Ocugen has over 95 employees. |
| Who is the CEO of Ocugen? | Ocugen's CEO is Shankar Musunuri. |
| Is Ocugen publicly listed? | Yes, Ocugen is a public company listed on Nasdaq. |
| What is the stock symbol of Ocugen? | Ocugen trades under OCGN ticker. |
| When did Ocugen go public? | Ocugen went public in 2014. |
| Who are competitors of Ocugen? | Ocugen main competitors are Zura Bio, Lexicon Pharmaceuticals, TTY Biopharm, uniQure. |
| What is the current market cap of Ocugen? | Ocugen's current market cap is $643M. |
| What is the current revenue of Ocugen? | Ocugen's last 12 months revenue is $4M. |
| What is the current revenue growth of Ocugen? | Ocugen revenue growth (NTM/LTM) is 150%. |
| What is the current EV/Revenue multiple of Ocugen? | Current revenue multiple of Ocugen is 167.8x. |
| Is Ocugen profitable? | No, Ocugen is not profitable. |
| What is the current net income of Ocugen? | Ocugen's last 12 months net income is ($69M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.